Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Assertio Therapeutics ( (ASRT) ) just unveiled an update.
On May 13, 2026, Assertio agreed to be acquired by Zydus Worldwide DMCC, which will launch an all-cash tender offer at $23.50 per share, valuing the deal at about $166.4 million and followed by a second-step merger that will take Assertio private and delist its shares from Nasdaq. The price represents a 30.6% premium to Assertio’s original Garda Therapeutics deal and a 75.8% premium to its unaffected share price, and the board, citing higher value and greater execution certainty, terminated its Garda merger, secured tender and support commitments from key holders, and set parallel terms to cash out equity awards and repurchase its $40 million convertible notes through a contingent note tender offer, tightening the company’s capital structure ahead of closing expected in the second quarter of 2026.
Under the agreed structure, all Assertio common shareholders who tender will receive the same cash consideration, with options and RSUs converted into cash and out-of-the-money options canceled, while completion is conditioned on a majority tender, minimum net cash of $95 million and the absence of legal barriers. Assertio faces a reverse $6.3 million break fee obligation in certain competing-bid scenarios and Zydus has already funded a $5.8 million fee to unwind the Garda agreement, underscoring the bidder’s commitment, while the parties plan a concurrent offer and consent solicitation to buy back convertible notes at par plus accrued interest and amend the indenture for any notes remaining outstanding after the merger.
The most recent analyst rating on (ASRT) stock is a Hold with a $23.50 price target. To see the full list of analyst forecasts on Assertio Therapeutics stock, see the ASRT Stock Forecast page.
Spark’s Take on ASRT Stock
According to Spark, TipRanks’ AI Analyst, ASRT is a Neutral.
The score is held back primarily by weak financial performance (revenue decline, sustained losses, and negative TTM cash flow). Offsetting this are constructive FY2026 guidance and positive Robodon-driven narrative from the earnings call, strong trend-following technicals (despite overbought signals), and a supportive near-term corporate backdrop from the all-cash acquisition process.
To see Spark’s full report on ASRT stock, click here.
More about Assertio Therapeutics
Assertio Holdings, Inc. is a pharmaceutical company with commercial capabilities focused on marketing differentiated products that address patient needs, primarily in the oncology market. The company’s business model centers on commercializing specialty therapeutics, positioning it within the broader branded pharmaceutical and oncology-focused therapies space.
Average Trading Volume: 226,421
Technical Sentiment Signal: Hold
Current Market Cap: $145.7M
For a thorough assessment of ASRT stock, go to TipRanks’ Stock Analysis page.